source
- Xenon shares tumble up to 30% after pausing depression trial over neuropsychiatric eventsXenon Pharmaceuticals announced it is pausing enrollment in its depression trial for the drug azetukalner after neuropsychiatric adverse events emerged that were not observed in earlier testing. A…
- Novo Nordisk acquires three early-stage obesity programs from KallyopeNovo Nordisk announced the purchase of three early-stage obesity drug programs from New York‑based biotech Kallyope, expanding its metabolic pipeline. The acquired assets are not GLP‑1 incretins.…